Lene Gerlach
Founder and Chairperson @ Women in Life Science Denmark
Copenhagen, Denmark
Lene Gerlach is a seed investor at Women in Life Science Denmark in Copenhagen focused on Health Care and Biotechnology. Lene Gerlach currently works as a Board Member for ArgusEye. She previously worked at Bestyrelseskvinder as a Member. Lene Gerlach attended Probana Business School.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Lene Gerlach invests in
Stages Lene Gerlach invests in
Countries Lene Gerlach invests in
Investment Focus
Industry
- Health Care 3 (50%)
- Biotechnology 3 (50%)
- Sensor 1 (17%)
- Medical 1 (17%)
- Software 1 (17%)
Stage
- Seed 3 (50%)
- Series A 1 (17%)
- Venture - Series Unknown 1 (17%)
Country
- Denmark 3 (50%)
- Sweden 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ArgusEye
|
ArgusEye is a biotechnology company that provides sensor solutions for real-time detection of biological systems and processes. ArgusEye's patented sensor technology is the result of extensive academic research and is based on nanoplasmonic sensing with fiber optics. By adding customized receptors, ArgusEye can offer flexible and sensitivesensing systems for a variety of targets. | $3M / Venture - Series Unknown / May 13, 2024 | |
Synklino
|
Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation. | $32M / Series A / Jun 08, 2022 | |
Octarine Bio
|
Octarine Bio is a synthetic biology company that produces superior cannabinoids for the pharmaceutical industry. | $1.2M / Seed / Mar 11, 2021 | |
|
Octarine Bio
|
Octarine Bio is a synthetic biology company that produces superior cannabinoids for the pharmaceutical industry. | $1.8M / Seed / Nov 12, 2020 | |
|
Synklino
|
Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation. | Seed / Sep 29, 2020 | |
Cerebriu
|
Cerebriu is a health tech company developing machine learning in medical imaging that improves workflow efficiency and quality in radiology.Its software solution Cerebriu Apollo achieves the company's aim by automating image acquisition protocols and triage during MRI brain acquisition providing decision support at key stages of thediagnostic process. The company covers findings of the brain, starting with brain MRI, including stroke, bleeds, and tumors, following MS, dementia, and TBI in brain CT. | $960K / Seed / May 08, 2020 |
Co-Investors
About Women in Life Science Denmark
WiLD is a networking platform for women in senior positions in business and academia that is motivating and focused on science.
Women in Life Science Denmark Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Lene Gerlach
Founder and Chairperson
|
|||
Kirsten Drejer
CEO and Co-Founder
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Lene Gerlach invest in?
Lene Gerlach invests primarily in Health Care, Biotechnology and Sensor startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Lene Gerlach last invest?
The most recent investment recorded for Lene Gerlach closed in May 2024. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
